Patricia Lugar, MD
Internal Medicine · Durham, NCNPI 1376741967
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Biocryst Pharmaceuticals, Inc. at 35.0% of the total. 2025 is the largest year on record at $75,292, 8.5 times the $8,831 reported in 2019. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $1343.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$69K
- Blueprint Medicines Corporation$57K
- Grifols USA, LLC$41K
- CSL Behring$18K
- Shire North American Group Inc$6K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- plus $2K from 6 others
Across 108 payments — averaging $5092.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$175K
- Biocryst Pharmaceuticals, Inc.$96K
- Shire North American Group Inc$91K
- Blueprint Medicines Corporation$87K
- Takeda Pharmaceuticals U.S.A., Inc.$66K
- Biomarin Pharmaceutical Inc.$35K
What the payments were for
- Consulting fees$89,40845%
- Speaking & faculty fees$86,31644%
- Travel & lodging$18,7219%
- Food & beverage$3,0082%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 27 | $69,124 |
| Blueprint Medicines Corporation | 38 | $56,866 |
| Grifols USA, LLC | 33 | $40,668 |
| CSL Behring | 20 | $18,340 |
| Shire North American Group Inc | 15 | $5,991 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $4,434 |
| Cycle Pharmaceuticals Inc | 1 | $1,370 |
| Biomarin Pharmaceutical Inc. | 1 | $229 |
| Grifols Shared Services North America, Inc. | 4 | $158 |
| Bio Products Laboratory USA, Inc. | 1 | $157 |
| Sanofi | 1 | $66 |
| Biocryst US Sales Co., LLC | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,453 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlvescoCiclesonide | 19 | $17,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,085 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,529 |
| Epinephrine | 13 | $2,825 |
| Cevimeline Hcl | 11 | $2,002 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $1,030 |
| Azithromycin | 19 | $517 |
| Montelukast Sodium | 39 | $488 |
| Potassium Chloride | 13 | $218 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Durham
- Nirmish ShahDurham$862K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Rebecca RichDurham$160K
- Adam DevoreDurham$112K
- Kevin ThomasDurham$101K
- Julius WilderDurham$97K
- Richard RiedelDurham$95K
- Jennifer RymerDurham$73K
- Jamie ToddDurham$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.